Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
54
NBY Quote, Financials, Valuation and Earnings
Last price:
$4.75
Seasonality move
:
-4.68%
Day range:
$5.10 - $5.99
52-week range:
$0.46 - $19.95
Dividend yield:
0%
P/E ratio:
9.21x
P/S ratio:
10.65x
P/B ratio:
1.50x
Volume:
1.3M
Avg. volume:
2.7M
1-year change:
576.54%
Market cap:
$691.4M
Revenue:
$9.8M
EPS (TTM):
$0.60
Analysts' Opinion
-
Consensus RatingNovaBay Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $0.85, NovaBay Pharmaceuticals, Inc. has an estimated downside of -84.49% from its current price of $5.48.
-
Price Target UpsideAccording to analysts, the highest upside price target is $0.85 representing -100% upside increase from its current price of $5.48.
Fair Value
-
According to the consensus of 1 analyst, NovaBay Pharmaceuticals, Inc. has -84.49% downside to fair value with a price target of $0.85 per share.
NBY vs. S&P 500
-
Over the past 5 trading days, NovaBay Pharmaceuticals, Inc. has underperformed the S&P 500 by -56.79% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NovaBay Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NovaBay Pharmaceuticals, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter NovaBay Pharmaceuticals, Inc. reported revenues of $521K.
Earnings Growth
-
NovaBay Pharmaceuticals, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter NovaBay Pharmaceuticals, Inc. reported earnings per share of -$0.22.
Enterprise value:
694.4M
EV / Invested capital:
--
Price / LTM sales:
10.65x
EV / EBIT:
--
EV / Revenue:
245.37x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-99.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.5M
Return On Assets:
-56.74%
Net Income Margin (TTM):
-280.92%
Return On Equity:
-306.03%
Return On Invested Capital:
-208.55%
Operating Margin:
-224.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $12M | $2.1M | $2.8M | -- | $521K | |
| Gross Profit | $6.8M | $808K | $1.5M | -$87K | $42K | |
| Operating Income | -$5.8M | -$6.6M | -$7.1M | -$1.7M | -$1.2M | |
| EBITDA | -$5.6M | -$6.2M | -$6.8M | -$1.6M | -$1.1M | |
| Diluted EPS | -$203.94 | -$60.90 | $0.60 | -$1.92 | -$0.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.5M | $10.6M | $8.2M | $2.3M | $2.9M | |
| Total Assets | $12.2M | $22.4M | $12.9M | $3.9M | $3.5M | |
| Current Liabilities | $2.9M | $3.7M | $4.6M | $2M | $1.4M | |
| Total Liabilities | $2.9M | $8.6M | $5.8M | $2.8M | $1.9M | |
| Total Equity | $9.4M | $13.8M | $7M | $1.1M | $1.6M | |
| Total Debt | $196K | $1.7M | $1.2M | $821K | $405K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5M | -$6.4M | -$7M | -$2.4M | -$1.8M | |
| Cash From Investing | -$16K | -$5K | -- | -- | -- | |
| Cash From Financing | $5.3M | $794K | -$2.8M | $2.1M | -$1.3M | |
| Free Cash Flow | -$5.1M | -$6.4M | -$7M | -$2.4M | -$1.8M | |
NBY
Sector
Market Cap
$691.4M
$26M
Price % of 52-Week High
27.47%
51.81%
Dividend Yield
0%
0%
Shareholder Yield
17.49%
-1.66%
1-Year Price Total Return
576.54%
-18.29%
Beta (5-Year)
0.093
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$10.57
200-day SMA
Buy
Level
$1.86
Bollinger Bands (100)
Buy
Level
-0.33 - 6.55
Chaikin Money Flow
Buy
Level
21M
20-day SMA
Sell
Level
$8.71
Relative Strength Index (RSI14)
Sell
Level
44.88
ADX Line
Buy
Level
60.72
Williams %R
Buy
Level
-97.4411
50-day SMA
Buy
Level
$4.48
MACD (12, 26)
Buy
Level
1.39
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
47.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.7248)
Sell
CA Score
(Annual)
Level (-2.9954)
Buy
Beneish M-Score
(Annual)
Level (-3.1863)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.6374)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.
Stock Forecast FAQ
In the current month, NBY has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NBY average analyst price target in the past 3 months is $0.85.
-
Where Will NovaBay Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that NovaBay Pharmaceuticals, Inc. share price will drop to $0.85 per share over the next 12 months.
-
What Do Analysts Say About NovaBay Pharmaceuticals, Inc.?
Analysts are divided on their view about NovaBay Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NovaBay Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to $0.85.
-
What Is NovaBay Pharmaceuticals, Inc.'s Price Target?
The price target for NovaBay Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $0.85 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NBY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NovaBay Pharmaceuticals, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of NBY?
You can purchase shares of NovaBay Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NovaBay Pharmaceuticals, Inc. shares.
-
What Is The NovaBay Pharmaceuticals, Inc. Share Price Today?
NovaBay Pharmaceuticals, Inc. was last trading at $4.75 per share. This represents the most recent stock quote for NovaBay Pharmaceuticals, Inc.. Yesterday, NovaBay Pharmaceuticals, Inc. closed at $5.48 per share.
-
How To Buy NovaBay Pharmaceuticals, Inc. Stock Online?
In order to purchase NovaBay Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NBY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NBY
Sector
P/E ratio
9.21x
23.85x
PEG ratio
--
-0.01x
P/B ratio
1.50x
1.83x
Price / LTM sales
10.65x
1.56x
Growth Metrics
NBY
Sector
Revenue growth
-1.61%
4.18%
Earnings growth
88.54%
9.66%
Revenue (5-year growth)
8.19%
6.28%
Earnings forecast
-$0.88
-$0.18
Profitability
NBY
Sector
Profitability FY 2024
$6.5M
$3.1M
Return on invested capital
-208.55%
-32.89%
Return on assets
-56.74%
-29.56%
Return on equity
-306.03%
-38.66%
Earnings Date
Last Earnings Date
Aug
12
Next Earnings Date
Jan
23
Estimated Next Earnings Date
Apr
24
Balance Sheet
NBY
Sector
Total cash
$2.3M
$25.2M
Short term investments
--
$25.1M
Total assets
$45.9M
$73M
Long term debt
$405K
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is down 2.6% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 8.03% over the past day.
Sell
24
INSP alert for Jan 23
Inspire Medical Systems, Inc. [INSP] is up 0.05% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
